Page 224 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 12 Cancer Chemotherapy 203

177. Kleihues P, Kolar GF, Margison GP: Interaction of the carcinogen possible receptor-mediated mechanism of doxorubicin cardiomy-
3,3-dimethyl-1-phenyltriazene with nucleic acids of various rat tis- opathy, Mol Pharmacol 37:503–514, 1990.
sues and the effect of a protein-free diet, Cancer Res 36:2189–2193, 198. Oakes SG, Schlager JJ, Santone KS, et al.: Doxorubicin blocks the
VetBooks.ir 178. Griessmayr PC, Payne SE, Winter JE, et al.: Dacarbazine as single- increase in intracellular Ca , part of a second messenger system
++
1976.
in n1e-115 murine neuroblastoma cells, J Pharmacol Exp Ther
252:979–983, 1990.
agent therapy for relapsed lymphoma in dogs, J Vet Intern Med
23:1227–1231, 2009. 199. Mau BL, Powis G: Inhibition of cellular thioredoxin reductase by
179. Flory AB, Rassnick KM, Al-Sarraf R, et al.: Combination of CCNU diaziquone and doxorubicin: relationship to the inhibition of cell
and DTIC chemotherapy for treatment of resistant lymphoma in proliferation and decreased ribonucleotide reductase activity, Bio-
dogs, J Vet Intern Med 22:164–171, 2008. chem Pharmacol 43:1621–1626, 1992.
180. Van Vechten M, Helfand SC, Jeglum KA: Treatment of relapsed 200. Morre DJ, Kim C, Paulik M, et al.: Is the drug-responsive nadh
canine lymphoma with doxorubicin and dacarbazine, J Vet Intern oxidase of the cancer cell plasma membrane a molecular target for
Med 4:187–191, 1990. adriamycin? J Bioenerg Biomembr 29:269–280, 1997.
181. Dervisis NG, Dominguez PA, Sarbu L, et al.: Efficacy of temo- 201. Terasaki T, Iga T, Sugiyama Y, et al.: Experimental evidence of char-
zolomide or dacarbazine in combination with an anthracycline for acteristic tissue distribution of adriamycin: tissue DNA concentra-
rescue chemotherapy in dogs with lymphoma, J Am Vet Med Assoc tion as a determinant, J Pharm Pharmacol 34:597–600, 1982.
231:563–569, 2007. 202. Nicolay K, Timmers RJM, Spoelstra E, et al.: The interaction of
182. Finotello R, Stefanello D, Zini E, et al.: Comparison of doxoru- adriamycin with cardiolipin in model and rat liver mitochondrial
bicin-cyclophosphamide with doxorubicin-dacarbazine for the membranes, Biochim Biophys Acta 778:359–371, 1984.
adjuvant treatment of canine hemangiosarcoma, Vet Comp Oncol 203. Goormaghtigh E, Chatelain P, Caspers J, et al.: Evidence of a spe-
15:25–35, 2017. cific complex between adriamycin and negatively-charged phos-
183. Dervisis NG, Dominguez PA, Newman RG, et al.: Treatment with pholipids, Biochim Biophys Acta 597:1–14, 1980.
dav for advanced-stage hemangiosarcoma in dogs, J Am Anim Hosp 204. Gustafson DL, Rastatter JC, Colombo T, et al.: Doxorubicin
Assoc 47:170–178, 2011. pharmacokinetics: macromolecule binding, metabolism and
184. Gale GR, Simpson JG, Smith AB: Studies of the mode of action of elimination in the context of a physiological model, J Pharm Sci
N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide, Cancer Res 91:1488–1501, 2002.
27:1186–1191, 1967. 205. Ahmed NK, Felsted RL, Bachur NR: Daunorubicin reduction
185. Moloney SJ, Wiebkin P, Cummings SW, et al.: Metabolic acti- mediated by aldehyde and ketone reductases, Xenobiotica 11:131–
vation of the terminal N-methyl group of N-isopropyl-alpha- 136, 1981.
(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine), 206. Pan SS, Bachur NR: Xanthine oxidase catalyzed reductive cleavage
Carcinogenesis 6:397–401, 1985. of anthracycline antibiotics and free radical formation, Mol Phar-
186. Schold SC, Brent TP, von Hofe E, et al.: O -alkylguanine-DNA macol 17:95–99, 1980.
6
alkyltransferase and sensitivity to procarbazine in human brain- 207. Eschalier A, Lavarenne J, Burtin C, et al.: Study of histamine release
tumor xenografts, J Neurosurg 70:573–577, 1989. induced by acute administration of antitumor agents in dogs, Can-
187. Shiba DA, Weinkam RJ: Quantitative analysis of procarbazine, cer Chemother Pharmacol 21:246–250, 1988.
procarbazine metabolites and chemical degradation products with 208. Thamm DH, Vail DM: Aftershocks of cancer chemotherapy: man-
application to pharmacokinetic studies, J Chromatogr B Biomed Sci aging adverse effects, J Am Anim Hosp Assoc 43:1–7, 2007.
Appl 229:397–407, 1982. 209. Billingham ME, Mason JW, Bristow MR, et al.: Anthracycline car-
188. Oliverio VT, Denham C, Devita VT, et al.: Some pharmaco- diomyopathy monitored by morphologic changes, Cancer Treat Rep
logic properties of a new antitumor agent, N-isopropyl-alpha- 62:865–872, 1978.
(2-methylhydrazino)-p-toluamide, hydrochloride (NSC-77213), 210. Alves de Souza RC, Camacho AA: Neurohormonal, hemodynamic,
Cancer Chemother Rep 42:1–7, 1964. and electrocardiographic evaluations of healthy dogs receiving long-
189. Chabner BA, Sponzo R, Hubbard S, et al.: High-dose intermittent term administration of doxorubicin, Am J Vet Res 67:1319–1325, 2006.
intravenous infusion of procarbazine (NSC-77213), Cancer Che- 211. Ghigo A, Li M, Hirsch E: New signal transduction paradigms
mother Rep 57:361–363, 1973. in anthracycline-induced cardiotoxicity, Biochim Biophys Acta
190. Northrup NC, Gieger TL, Kosarek CE, et al.: Mechlorethamine, 1863:1916–1925, 2016.
procarbazine and prednisone for the treatment of resistant lym- 212. Chatterjee K, Zhang J, Honbo N, et al.: Doxorubicin cardiomy-
phoma in dogs, Vet Comp Oncol 7:38–44, 2009. opathy, Cardiology 115:155–162, 2010.
191. Brown PM, Tzannes S, Nguyen S, et al.: Lopp chemotherapy as a 213. Pessah IN, Durie EL, Schiedt MJ, et al.: Anthraquinone-sensitized
first-line treatment for dogs with T-cell lymphoma, Vet Comp Oncol Ca release channel from rat cardiac sarcoplasmic reticulum: pos-
2+
16:108–113, 2018. sible receptor-mediated mechanism of doxorubicin cardiomyopa-
192. Zunino F, Gambetta R, Di Marco A: The inhibition in vitro of thy, Mol Pharmacol 37:503–514, 1990.
DNA polymerase and rna polymerase by daunomycin and adria- 214. Zhang S, Liu X, Bawa-Khalfe T, et al.: Identification of the molecu-
mycin, Biochem Pharmacol 24:309–311, 1975. lar basis of doxorubicin-induced cardiotoxicity, Nat Med 18:1639–
193. Tewey KM, Chen GI, Nelson EM, et al.: Intercalative anti-tumor 1642, 2012.
drugs interfere with the breakage-reunion reaction of mammalian 215. Zhao L, Zhang B: Doxorubicin induces cardiotoxicity through
DNA topoisomerase, J Biol Chem 259:9182–9187, 1984. upregulation of death receptors mediated apoptosis in cardiomyo-
194. Taatjes DJ, Gaudiano G, Resing K, et al.: Alkylation of DNA by cytes, Sci Rep 7:44735, 2017.
the anthracycline, antitumor drugs adriamycin and daunomycin, 216. FitzPatrick WM, Dervisis NG, Kitchell BE: Safety of concurrent
J Med Chem 39:4135–4138, 1996. administration of dexrazoxane and doxorubicin in the canine can-
195. Doroshow JH: Role of hydrogen peroxide and hydroxyl radical in cer patient, Vet Comp Oncol 8:273–282, 2010.
the killing of ehrlich tumor cells by anticancer quinones, Proc Natl 217. O’Keefe DA, Sisson DD, Gelberg HB, et al.: Systemic toxicity
Acad Sci USA 83:4514–4518, 1985. associated with doxorubicin administration in cats, J Vet Intern Med
196. Bachur NR, Gordon SL, Gee MV: A general mechanism for micro- 7:309–317, 1993.
somal activation of quinone anticancer agents to free radicals, Can- 218. Foye WO, Vajragupta O, Sengupta SK: DNA-binding specificity
cer Res 38:1745–1750, 1978. and rna polymerase inhibitory activity of bis(aminoalkyl)anthra-
197. Pessah IN, Durie EL, Schiedt MJ, et al.: Anthraquinone-sensitized quinones and bis(methylthio)vinylquinolinium iodides, J Pharm
++
Ca release channel from rat cardiac sarcoplasmic reticulum: Sci 71:253–257, 1982.